Table 2

Cox regression of IMRS and CHA2DS2-VASc associations with non-fatal stroke or mortality and with each endpoint individually

SexIndependentpredictorsUnivariableBivariableMultivariable
HR(95% CI)HR(95% CI) HR (95% CI)
Primary study endpoint: non-fatal stroke or all-cause mortality
 Women
IMRS, moderate vs low risk2.81 (2.39 to 3.30)*2.21 (1.87 to 2.61)*2.04 (1.72 to 2.42)*
IMRS, high vs low risk7.14 (6.03 to 8.45)*5.19 (4.35 to 6.20)*4.46 (3.71 to 5.35)*
CHA2DS2-VASc, 2 vs 11.81 (1.30 to 2.53)*1.50 (1.08 to 2.10)†1.45 (1.04 to 2.03)†
CHA2DS2-VASc, >2 vs 14.94 (3.67 to 6.65)*2.75 (2.03 to 3.73)*2.46 (1.81 to 3.35)*
 Men (CHA2DS2-VASc low-risk category based on European guidelines)
IMRS, moderate vs low risk2.87 (2.57 to 3.20)*2.06 (1.84 to 2.31)*1.86 (1.66 to 2.09)*
IMRS, high vs low risk7.25 (6.38 to 8.25)*4.54 (3.96 to 5.21)*3.67 (3.19 to 4.23)*
CHA2DS2-VASc, 1 vs 02.89 (2.13 to 3.93)*2.42 (1.77 to 3.31)*2.22 (1.62 to 3.05)*
CHA2DS2-VASc, 2 vs 04.83 (3.61 to 6.48)*3.48 (2.58 to 4.71)*3.05 (2.25 to 4.15)*
CHA2DS2-VASc, >2 vs 09.78 (7.38 to 12.97)*5.74 (4.27 to 7.71)*4.61 (3.40 to 6.26)*
 Men (CHA2DS2-VASc low-risk category based on American guidelines)
IMRS, moderate vs low risk2.87 (2.57 to 3.20)*2.15 (1.92 to 2.41)*1.99 (1.77 to 2.23)*
IMRS, high vs low risk7.25 (6.38 to 8.25)*4.72 (4.12 to 5.41)*4.10 (3.56 to 4.72)*
CHA2DS2-VASc, 2 vs <22.25 (1.94 to 2.62)*1.77 (1.52 to 2.06)*1.71 (1.46 to 2.00)*
CHA2DS2-VASc, >2 vs <24.55 (4.00 to 5.18)*2.90 (2.53 to 3.33)*2.80 (2.42 to 3.23)*
Secondary study endpoint: non-fatal stroke
 Women
IMRS, moderate vs low risk1.19 (0.88 to 1.60)0.96 (0.70 to 1.32)0.92 (0.67 to 1.26)
IMRS, high vs low risk1.44 (0.99 to 2.10)1.08 (0.73 to 1.61)0.96 (0.64 to 1.45)
CHA2DS2-VASc, 2 vs 11.19 (0.63 to 2.24)1.19 (0.63 to 2.26)1.10 (0.58 to 2.09)
CHA2DS2-VASc, >2 vs 12.18 (1.27 to 3.75)†2.17 (1.24 to 3.82)†1.87 (1.08 to 3.24)†
 Men (CHA2DS2-VASc low-risk category based on European guidelines)
IMRS, moderate vs low risk1.39 (1.07 to 1.82)†1.05 (0.80 to 1.39)1.01 (0.76 to 1.33)
IMRS, high vs low risk2.86 (2.01 to 4.07)*1.92 (1.33 to 2.78)*1.68 (1.15 to 2.44)†
CHA2DS2-VASc, 1 vs 04.36 (1.97 to 9.66)*4.25 (1.92 to 9.43)*4.17 (1.87 to 9.29)*
CHA2DS2-VASc, 2 vs 04.39 (2.00 to 9.62)*4.15 (1.88 to 9.15)*4.13 (1.86 to 9.17)*
CHA2DS2-VASc, >2 vs 07.76 (3.64 to 16.54)*6.79 (3.13 to 14.70)*6.87 (3.15, 15.01)*
 Men (CHA2DS2-VASc low-risk category based on American guidelines)
IMRS, moderate vs low risk1.39 (1.07 to 1.82)†1.11 (0.84 to 1.47)1.07 (0.81 to 1.41)
IMRS, high vs low risk2.86 (2.01 to 4.07)*2.02 (1.39 to 2.93)*1.84 (1.27 to 2.69)†
CHA2DS2-VASc, 2 vs <21.45 (0.99 to 2.10)1.37 (0.94 to 2.00)1.32 (0.90 to 1.93)
CHA2DS2-VASc, >2 vs <22.55 (1.87 to 3.48)*2.22 (1.59 to 3.09)*2.19 (1.56 to 3.08)*
Secondary study endpoint: all-cause mortality
 Women
IMRS, moderate vs low risk3.40 (2.83 to 4.07)*2.65 (2.19 to 3.19)*2.43 (2.01 to 2.94)*
IMRS, high vs low risk9.21 (7.64 to 11.11)*6.62 (5.44 to 8.05)*5.67 (4.62 to 6.94)*
CHA2DS2-VASc, 2 vs 12.03 (1.39 to 2.94)*1.62 (1.11 to 2.35)†1.56 (1.07 to 2.28)†
CHA2DS2-VASc, >2 vs 15.94 (4.24 to 8.30)*3.03 (2.15 to 4.28)*2.80 (1.98 to 3.96)*
 Men (CHA2DS2-VASc low-risk category based on European guidelines)
IMRS, moderate vs low risk3.19 (2.84 to 3.58)*2.26 (2.00 to 2.55)*2.04 (1.81 to 2.30)*
IMRS, high vs low risk8.30 (7.25 to 9.49)*5.10 (4.42 to 5.88)*4.16 (3.59 to 4.81)*
CHA2DS2-VASc, 1 vs 02.84 (2.04 to 3.96)*2.34 (1.67 to 3.29)*2.12 (1.51 to 2.99)*
CHA2DS2-VASc, 2 vs 05.18 (3.79 to 7.10)*3.61 (2.61 to 5.00)*3.12 (2.24 to 4.34)*
CHA2DS2-VASc, >2 vs 010.83 (7.99 to 14.67)*6.06 (4.41 to 8.33)*4.75 (3.43 to 6.60)*
 Men (CHA2DS2-VASc low-risk category based on American guidelines)
IMRS, moderate vs low risk3.19 (2.84 to 3.58)*2.36 (2.09 to 2.66)*2.16 (1.91 to 2.44)*
IMRS, high vs low risk8.30 (7.25 to 9.49)*5.29 (4.59 to 6.10)*4.60 (3.97 to 5.32)*
CHA2DS2-VASc, 2 vs <22.44 (2.08 to 2.86)*1.87 (1.59 to 2.21)*1.79 (1.52 to 2.11)*
CHA2DS2-VASc, >2 vs <25.10 (4.34 to 5.85)*3.14 (2.71 to 3.63)*2.97 (2.55 to 3.46)*

  • IMRS, Intermountain Mortality Risk Score.